|  |  | 

India Top Headlines

Antiviral drug ‘Clevira’ reused for the treatment of patients with mild to moderate Covid-19 | India News


NEW DELHI: Clevira, a drug developed primarily to treat dengue fever, has been repurposed as a supportive treatment for mild to moderate Covid-19 cases, its maker Apex Laboratories Private Limited said on Friday. The drug is effective when taken orally and the dose is one tablet twice a day after meals for 14 days. The drug has also been shown to be safe for liver and kidney parameters, he said.
“Clevira, an antiviral formulation, has received regulatory approval as a supportive treatment for mild to moderate Covid-19 cases,” the Chennai-based pharmaceutical company said.
“Clevira was developed primarily to treat dengue patients in 2017. Last year, when Covid-19 cases increased in the country, it was reused as a supportive treatment for mild to moderate coronavirus symptoms. The product is available in all over India and is priced at Rs. 11 per tablet, “the company said.
A clinical trial was conducted in 100 people between May and June last year and the results were “promising,” he said.
The 100 selected participants were randomized into two groups with 50 patients each during the 30-day trial conducted at Government Medical College Omandurar and Government Estate in Chennai after approval from the government of Tamil Nadu.
The control group consisted of patients diagnosed with SARS-CoV-2 infection and received standard care treatment as per hospital regulation as well as WHO / Indian Council for Medical Research (ICMR) guidelines.
Patients in the test group also received Clevira tablets twice daily by mouth after food for 14 days.
“Clevira was found to significantly reduce the time required for clinical recovery, which was observed in terms of reduction of pyrexia or body pain, normalization of respiratory rate (less than 24 / minute) and improvement in oxygen saturation level (more than 94 percent), “the company said.
Additionally, 86 percent of the patients tested negative for the infection on (day 5) and 100 percent of the patients tested negative for Covid-19 RT-PCR test on (day 10) after consuming tablets. by Clevira.
The results of the clinical trial were sent to the government of Tamil Nadu, the ICMR and the Ministry of AYUSH in 2020.
“After rigorous scrutiny and deliberations, the drug obtained approval to be used as a supportive measure for the treatment of mild to moderate symptoms of Covid-19 by regulators from the Ministry of AYUSH, a unique approval in its kind in India through various stages of scrutiny at the Central Council for Research in Ayurvedic Sciences (CCRAS) and the Interdisciplinary Technical Review Committee (ITRC), “the company said.
C Arthur Paul, International Business Manager, Apex Laboratories, said: “The antiviral drug significantly increases the white blood cell (WBC), platelet and lymphocyte counts within the normal range, in addition to reducing the viral load, hence the recovery of all the signs and symptoms. It’s much faster. ”
The significant reduction in erythrocyte sedimentation rate (ESR) is evident that the drug causes anti-inflammatory properties, he said.
“Clevira has been shown to be effective as an analgesic, antipyretic and for the reversal of thrombocytopenia. It is absolutely safe for people with liver or kidney disease and can be safely co-administered with other medications. It can also be used as a prophylactic treatment for primary contacts of Covid-19 positive patients and front-line healthcare workers, “the official noted.
The drug is recommended for all age groups from 2 years old, added Paul.
The company said that the drug is available throughout India.

Times of India